GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2013

Bayer Taps ChromoTek’s Drug Profiling Technology

  • Bayer Pharma has gained the right to use ChromoTek’s Cell Cycle Chromobody® technology for drug profiling by high-content analysis. Bayer will apply Chromobody technology for real-time monitoring of cell cycle progression in drug discovery.

    ChromoTek’s Chromobody technology is a universal live-cell imaging technology for high-content analysis. Chromobodies are single-domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody technology allows users to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells.

    ChromoTek says that currently available Chromobodies trace cellular processes like cell cycle, apoptosis, DNA damage and repair, or allow cytoskeletal analysis. The Cell Cycle Chromobody cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a noninvasive manner while providing full flexibility to multiplex with other procedures, the firm reports.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?